《美股業績》化工巨擘陶氏季績及收入預測均勝預期
道指成分股、美國化工巨擘陶氏(Dow Inc.)(DOW.US)公佈第三季業績。季度純利16.83美元,對上年度同期虧損2,500萬美元。每股季度攤薄純利2.23美元,經調整後爲2.75美元,高於市場預期的2.55美元。季度收入148.37億美元,按年升53%,高於市場預期的142.8億美元。
公司去年同期錄得重組及資產相關開支6.17億美元,以及分析及合併成本6,300萬美元。公司第三季產品價格按年升50%,銷量則按年升2%。公司預期包裝與特殊塑料、塗層及工業部門季內淨銷售按季持平至下跌3%,受原料及能源成本上漲影響。
公司預計現季度銷售介乎140億至145億美元,高於市場預期的135.3億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.